|
SomaLogic
multiplex aptamer-based proteomic platform Multiplex Aptamer Based Proteomic Platform, supplied by SomaLogic, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/multiplex aptamer-based proteomic platform/product/SomaLogic Average 90 stars, based on 1 article reviews
multiplex aptamer-based proteomic platform - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
SomaLogic
aptamer-based proteomic somascan® platform Aptamer Based Proteomic Somascan® Platform, supplied by SomaLogic, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/aptamer-based proteomic somascan® platform/product/SomaLogic Average 90 stars, based on 1 article reviews
aptamer-based proteomic somascan® platform - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
SomaLogic
5k aptamer-based proteomics platform ![]() 5k Aptamer Based Proteomics Platform, supplied by SomaLogic, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/5k aptamer-based proteomics platform/product/SomaLogic Average 90 stars, based on 1 article reviews
5k aptamer-based proteomics platform - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
SomaLogic
somascan v4.1 assay, an aptamer-based quantitative proteomic biomarker discovery platform ![]() Somascan V4.1 Assay, An Aptamer Based Quantitative Proteomic Biomarker Discovery Platform, supplied by SomaLogic, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/somascan v4.1 assay, an aptamer-based quantitative proteomic biomarker discovery platform/product/SomaLogic Average 90 stars, based on 1 article reviews
somascan v4.1 assay, an aptamer-based quantitative proteomic biomarker discovery platform - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
SomaLogic
aptamer-based proteomic somascan platform ![]() Aptamer Based Proteomic Somascan Platform, supplied by SomaLogic, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/aptamer-based proteomic somascan platform/product/SomaLogic Average 90 stars, based on 1 article reviews
aptamer-based proteomic somascan platform - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
SomaLogic
aptamer-based proteomic platform ![]() Aptamer Based Proteomic Platform, supplied by SomaLogic, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/aptamer-based proteomic platform/product/SomaLogic Average 90 stars, based on 1 article reviews
aptamer-based proteomic platform - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
SomaLogic
aptamer-based 1.3k target proteomics platform ![]() Aptamer Based 1.3k Target Proteomics Platform, supplied by SomaLogic, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/aptamer-based 1.3k target proteomics platform/product/SomaLogic Average 90 stars, based on 1 article reviews
aptamer-based 1.3k target proteomics platform - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
SomaLogic
multiplexed aptamer-based proteomic platform v3.1 ![]() Multiplexed Aptamer Based Proteomic Platform V3.1, supplied by SomaLogic, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/multiplexed aptamer-based proteomic platform v3.1/product/SomaLogic Average 90 stars, based on 1 article reviews
multiplexed aptamer-based proteomic platform v3.1 - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
Journal: European Heart Journal. Digital Health
Article Title: Multimodal data integration to predict atrial fibrillation
doi: 10.1093/ehjdh/ztae081
Figure Lengend Snippet: Model development. ( A ) Numbers of participants from different data sources. Diagrams represent the numbers of participants from each of the four data sources for incident AF after Visit 3 (left) and prevalent AF at Visit 5 (right). The combined datasets are intersections among participants in the four data sources, consisting of the test set (consistent across the combined data and four data sources) and the combined training set. For all four data sources, we excluded non-White or Black participants, Black participants in Washington County and Minneapolis centres due to low numbers. We also excluded participants with atrial fibrillation rhythm on the source ECG or poor ECG quality. CRS, clinical risk score; PRS, polygenic risk score; ECG, electrocardiogram model; Prot, protein score. ( B ) Model development diagram. CRS represents the predicted score generated by logistic regression utilizing 11 clinical variables: age, race, height, weight, systolic blood pressure, diastolic blood pressure, current smoking, antihypertensive medication use, diabetes, prevalent heart failure, and prevalent myocardial infarction. PRS was derived with weights provided in a study based on AF GWAS across six cohorts. Combined models integrated information from different combinations of data source. For genotype, ECG, and proteomics, combined models incorporate the risk scores from each data source. For clinical variables, the combined models directly utilized the 11 clinical variables themselves instead of the CRS, proved to produce better prediction performance. ( C ) Diagram of data integration design. Test data remained consistent for comparing both separate and combined models within the same replicate. Sample sizes for incident AF after Visit 3 and prevalent AF at Visit 5 are listed for each dataset. In the case of separate training data for ECG, we additionally partitioned it to network training and validation sets by a ratio of 0.9:0.1. For separate training data regarding proteomics, we employed five-fold cross-validation to choose from 10 values of lasso penalty parameters.
Article Snippet: Participant plasma samples from Visit 3 and Visit 5 were stored at −80°C after initial collection and thawed for analysis with the
Techniques: Generated, Derivative Assay